Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib September 28, 2022
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines September 28, 2022
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma September 13, 2022
Oxford BioTherapeutics Announces Collaboration with Agenus toSupport the Clinical Development of OBT’s Antibody DrugConjugate OBT076 in combination with Agenus CPI Balstilimab June 14, 2022
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) June 13, 2022
Incyclix Bio Announces $30M Series B Financing to Support Clinical Development of INX-315 April 1, 2022
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates March 5, 2022
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked ADC Candidates December 23, 2021
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance ADG106 in Combination with KEYTRUDA August 20, 2021
Adagene Announces Clinical Trial Collaboration With Merck to Advance ADG116 and ADG126 in Combination with KEYTRUDA July 25, 2021
Exelixis and Adagene to Develop Novel Masked ADCs with Improved Safety and Efficacy Profiles February 6, 2021
ARC Therapeutics Launched to Develop CDK Inhibitors for the Treatment of Advanced and Resistant Cancers August 6, 2020
TC BioPharm Partners with Trinity College Dublin to Develop V Delta 1 γδ T Cell-based Cancer Treatments February 26, 2019
